Lipid Disorders
From the Journals
Test Lp(a) levels to inform ASCVD management: NLA statement
“The question in the scientific community is: What role does that particular biomarker play in terms of causing serious heart disease, stroke, and...
Conference Coverage
No invasive strategy benefit at 5 years in ISCHEMIA-CKD extension study
The trial speaks to the lofty high-risk status of patients with CAD. ‘You’re seeing in a group of patients, with largely preserved EF but advanced...
From the Journals
Artificial sweeteners linked to higher CV event risk
The first study to include artificial sweetener from all sources, not just drinks, may increase concerns about these agents. But not all are...
Latest News
Candy, desserts: A ‘gateway’ to unhealthy eating among teens
Over the past 30 years, there’s been a steady increase in consumption of ultra-processed foods worldwide, coupled with mounting evidence that...
Opinion
Muscling through the data
Sometimes no amount of solid data will change the mind of someone who’s already made theirs up.
Conference Coverage
Majority of muscle symptoms with statins not caused by treatment
A new Cholesterol Trialists Collaboration meta-analysis shows that in 14 of the 15 people who experience muscle pain or weakness when taking a...
Conference Coverage
Evolocumab benefits accrue with longer follow-up: FOURIER OLE
Chief among the benefits was a reduction in cardiovascular mortality not observed in the pivotal trial that led to U.S. approval of evolocumab.
From the Journals
Omega-3 fatty acids and depression: Are they protective?
In the fully adjusted model, consumption of fatty acids from the omega-3 family had a protective effect against maintenance of depressive episodes...
From the Journals
Drinking black tea linked to lower risk of dying from cardiovascular disease
“While these findings may offer reassurance to tea drinkers, they do not indicate that people should start drinking tea or change their tea...
Guidelines
ACC fills gaps on guidance for nonstatin therapies for LDL-C lowering
The new guidance addresses the role of nonstatin therapies for lowering LDL-C, which were not addressed in the 2018 ACC/AHA guideline on...
Conference Coverage
AXIOMATIC-SSP: Cautious optimism on factor XI inhibitor in stroke
The new factor XI inhibitor antithrombotic, milvexian, showed promising results in a dose-finding phase 2 trial in patients with acute ischemic...